Document is current
Any future updates will be listed below
-
Authors
Alsaadi, Taoufik https://orcid.org/0000-0002-7513-5706
Al Madani, AbuBakar
Alhatou, Mohammed
Nada, Mona
Albilali, Abdulrazaq
Al-Qassabi, Ahmed
Mohamed, Hegab
Mohamed, Haytham https://orcid.org/0000-0002-2883-3317
El Masry, Rowan
Saifuddin, Ghaidaa Ahmed
AlRukn, Suhail Abdullah
- License Information
-
More Information
Article History
Received: 24 September 2024
Accepted: 20 November 2024
First Online: 30 December 2024
Declarations
:
: Taoufik Alsaadi received consultancy fees, speaker fees, and research grants from Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc, H.Lundbeck A/S, Pfizer Inc., and AbbVie Inc.; Mohammed Alhatou received consultancy fees, speaker fees, and research grants from Novartis AG, Eli Lilly and Company, Astra AB, H.Lundbeck A/S, Pfizer Inc., and AbbVie Inc. He received support for attending AAN, ECTRIMS, and EAN meetings and related travel expenses. Mona Nada received consultancy fees, travel support, and speaker fees from Novartis AG, Eli Lilly and Company, and Pfizer Inc.; she is also a co-chair of the Cluster Headache Special Interest Group in the International Headache Society; Ahmed Al-Qassabi received consultancy fees and speaker fees from Novartis AG, Pfizer Inc., Biogen Inc., and AbbVie Inc.; Hegab Mohamed, Haytham Mohamed, Ghaidaa Ahmed Saifuddin, and Rowan El Masry are employees of Pfizer Inc. The remaining authors (AbuBakar Al Madani, Abdulrazaq Albilali, and Suhail Abdullah AlRukn) do not have any financial disclosures or conflicts of interest to declare.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
